Triptolide analogues
AssigneeAderis Pharmaceuticals, Inc.
InventorGevork Minaskanian
Life of this patent
Estimating the term…
Abstract
Triptolide analogues are described, including compounds of Formula I: 1 or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R3-R6, X and Y are set forth in the specification. The compounds of the invention are potent 15-lipoxygenase inducers. Pharmaceutical compositions of the compounds are also described. Also provided are methods for the treatment or prophylaxis of inflammatory and autoimmune disorders in a mammal by administering compounds of the invention.
Claims86
A compound of Formula I:
- 37
- or a solvate, hydrate or pharmaceutically acceptable salt thereof;
- wherein:
- (a) each dotted line indicates the presence of either a single bond or double bond, wherein the valences of a single bond are completed by hydrogens;
- (b) X is O, S, or NR11, where R11 is hydrogen or alkyl;
- (c) R3, R4, R5, and R6 are independently hydrogen or alkyl;
- (d) R12 is hydrogen, alkyl, carboxylalkyl, or R12 is absent;
- and
- (e) Y, together with the two ring carbon atoms to which it is attached, represents a 5- to 7-membered monocyclic carbon ring which is saturated, partially saturated, or aromatic.
A compound of Formula II:
- 39
- or a solvate, hydrate or pharmaceutically acceptable salt thereof;
- wherein:
- (a) the dotted line indicates the presence of either a single bond or double bond, wherein the valences of a single bond are completed by hydrogens;
- (b) X is O, S, or NR11, where R11 is hydrogen or alkyl;
- (c) R1, R4, R5, and R6 are independently hydrogen or alkyl;
- (d) R12 is hydrogen, alkyl, carboxylalkyl, or R12 is absent;
- and
- (e) Y, together with the two ring carbon atoms to which it is attached, represents a 5- to 7-membered monocyclic carbon ring which can be saturated, partially saturated, or aromatic.
A compound of Formula III:
- 41
- or a solvate, hydrate or pharmaceutically acceptable salt thereof;
- wherein:
- (a) X is O, S, or NR11, where R11 is hydrogen or alkyl;
- (b) R1, R2, R5, and R6 are independently hydrogen or alkyl;
- (c) R12 is hydrogen, alkyl, carboxylalkyl, or R12 is absent;
- and
- (d) Y, together with the two ring carbon atoms to which it is attached, represents a 5- to 7-membered monocyclic carbon ring which can be saturated, partially saturated, or aromatic.
A compound of Formula IV:
- 43
- or a solvate, hydrate or pharmaceutically acceptable salt thereof;
- wherein:
- (a) X is O, S, or NR11, where R11 is hydrogen or alkyl;
- (b) R5 and R6 are independently hydrogen or alkyl;
- (c) R12 is hydrogen, alkyl, carboxylalkyl, or R12 is absent;
- and
- (d) Y1 and Y2 each represent, together with the two ring carbon atoms to which each is attached, a 5- to 7-membered monocyclic carbon ring which can be saturated, partially saturated, or aromatic.
A compound of Formula V:
- 45
- or a solvate, hydrate or pharmaceutically acceptable salt thereof;
- wherein:
- (a) the dotted line indicates the presence of either a single bond or double bond, wherein the valences of a single bond are completed by hydrogens;
- (b) X is O, S, or NR11, where R11 is hydrogen or alkyl;
- (c) R5, R7, R8, R9, and R10 are independently hydrogen or alkyl;
- (d) R12 is hydrogen, alkyl, carboxylalkyl, or R12 is absent;
- (e) Y1 represents, together with the two ring carbon atoms to which it is attached, a 5- to 7-membered monocyclic carbon ring which can be saturated, partially saturated, or aromatic;
- and
- (f) Y2 represents, together with the three ring carbon atoms to which it is attached, a 5- to 7-membered monocyclic carbon ring which can be saturated, partially saturated, or aromatic.
A compound of Formula VI:
- 47
- or a solvate, hydrate or pharmaceutically acceptable salt thereof;
- wherein:
- (a) the dotted line indicates the presence of either a single bond or double bond, wherein the valences of a single bond are completed by hydrogens;
- (b) X1 and X2 are independently O, S, or NR11, where R11 is hydrogen or alkyl;
- (c) R3, R4, R1 and R6 are independently hydrogen or alkyl;
- (d) R12 is hydrogen, alkyl, carboxylalkyl, or R12 is absent;
- and
- (e) Y, together with the two ring carbon atoms to which it is attached, represents a 5- to 7-membered monocyclic carbon ring which can be saturated, partially saturated, or aromatic.
A compound of Formula VII:
- 49
- or a solvate, hydrate or pharmaceutically acceptable salt thereof;
- wherein:
- (a) X1 and X3 are independently O, S, or NR11, where R11 is hydrogen or alkyl;
- (b) R1, R2, R5, and R6 are independently hydrogen or alkyl;
- (c) R12 is hydrogen, alkyl, carboxylalkyl, or R12 is absent;
- and
- (d) Y, together with the two ring carbon atoms to which it is attached, represents a 5- to 7-membered monocyclic carbon ring which can be saturated, partially saturated, or aromatic.
A compound of Formula VIII:
- 51
- or a solvate, hydrate or pharmaceutically acceptable salt thereof;
- wherein:
- (a) the dotted line indicates the presence of either a single bond or double bond, wherein the valences of a single bond are completed by hydrogens;
- (b) X1 and X2 are independently O, S, or NR11, where R11 is hydrogen or alkyl;
- (c) R3 and R5 are independently hydrogen or alkyl;
- (d) R12 is hydrogen, alkyl, carboxylalkyl, or R12 is absent;
- (e) Y, together with the two ring carbon atoms to which it is attached, represents a 5- to 7-membered monocyclic carbon ring which can be saturated, partially saturated, or aromatic;
- and
- (f) n is from 3 to 5.
A compound of Formula IX:
- 53
- or a solvate, hydrate or pharmaceutically acceptable salt thereof;
- wherein:
- (a) X1 and X3 are independently O, S, or NR11, where R11 is hydrogen or alkyl;
- (b) R3, R4, R5, and R6 are independently hydrogen or alkyl;
- (c) R12 is hydrogen, alkyl, carboxylalkyl, or R12 is absent;
- and
- (d) n is from 3 to 5.
A compound of Formula X:
- 55
- or a solvate, hydrate or pharmaceutically acceptable salt thereof;
- wherein:
- (a) X1, X2, and X3 are independently O, S, or NR11, where R11 is hydrogen or alkyl;
- (b) R3, R4, R5, and R6 are independently hydrogen or alkyl;
- (c) R12 is hydrogen, alkyl, carboxylalkyl, or R2 is absent;
- and
- (d) n is from 3 to 5.
A compound of Formula XI:
- 57
- or a solvate, hydrate or pharmaceutically acceptable salt thereof;
- wherein:
- (a) X1, X2, and X3 are independently O, S, or NR11, where R11 is hydrogen or alkyl;
- (b) R5, R6, and R7 are independently hydrogen or alkyl;
- and
- (c) n and n′ are each from 3 to 5.
A compound of Formula XII:
- 59
- or a solvate, hydrate or pharmaceutically acceptable salt thereof;
- wherein:
- (a) X1, X2, and X3 are independently O, S, or NR11, where R11 is hydrogen or alkyl;
- (b) R5 and R7 are independently hydrogen or alkyl;
- and
- (c) n, n′ and n″ are each from 3 to 5.
A compound of Formula XIII:
- 61
- or a solvate, hydrate or pharmaceutically acceptable salt thereof;
- wherein:
- (a) X1, X2, and X3 are independently O, S, or NR11, where R11 is hydrogen or alkyl;
- (b) R3, R5, and R7 are independently hydrogen or alkyl;
- and
- (c) n and n′ are each from 3 to 5.
A compound of Formula XIV:
- 63
- or a solvate, hydrate or pharmaceutically acceptable salt thereof;
- wherein:
- (a) X is O, S, or NR11, where R11 is hydrogen or alkyl;
- (b) R2, R3, R4, R5, and R6 are independently hydrogen or alkyl;
- and
- (c) n is from 3 to 5.
A compound of Formula XV:
- 65
- or a solvate, hydrate or pharmaceutically acceptable salt thereof, wherein:
- (a) X1 and X3 are independently O, S, or NR11, where R11 is hydrogen or alkyl;
- and
- (b) R1, R2, R3, R4, R4a, R5, R6, and R7 are independently hydrogen or alkyl.
A compound of Formula XVI:
- 67
- or a solvate, hydrate or pharmaceutically acceptable salt thereof;
- wherein:
- (a) X1, X2, and X3 are independently O, S, or NR11, where R11 is hydrogen or alkyl;
- (b) R2, R3, and R5 are independently hydrogen or alkyl;
- and
- (c) n and n′ are each from 3 to 5.
A compound of Formula XVII:
- 69
- or a solvate, hydrate or pharmaceutically acceptable salt thereof;
- wherein:
- (a) X1, X2, and X3 are independently O, S, or NH;
- (b) R2, R3, R4, and R5 are independently hydrogen or alkyl;
- (c) R12 is hydrogen, alkyl, carboxylalkyl, or R12 is absent;
- and
- (d) Y, together with the two ring carbon atoms to which it is attached, represents a 5- to 7-membered monocyclic carbon ring which is saturated, or partially saturated.
Dependencies are inferred from the claim text.